AUSTRALIAN medical cannabis sales tanked by over a quarter in the second half of 2025, following a clampdown on the previous ‘profit before patient’ model A report from the Penington Institute shows that medical cannabis sales peaked in the second half of 2024 at 3.72m units before falling to 2.65m units in the second half…
The company has received Ethics Approval from Bellberry Human Research Ethics Committee in Australia.
The company has won the contract following the country’s announcement that insurance for medical cannabis will be mandatory.
Flora Growth has provided an update to its international commercial cannabis export business.
Chill Brands has confirmed a new sales distribution partner and an expansion of its US retail store programme.
NORML has said the development should cause reflection for US lawmakers, stating that current federal cannabis policy in many states “aren’t notably different than the stance held by Putin’s regime in Russia”.
Astrasana Holding AG has secured a supply agreement.
The National Hemp Association (NHA) has been engaging with the United Nations (UN), the Food and Agriculture Organization (FAO), the International Fund for Agricultural Development (IFAD) and the World Bank to advance the recognition and acceptance of industrial hemp around the globe.
Cannatrek has ranked highly in Deloitte Technology Fast 50 Australia.
